BMRN vs. KNSA

Last updated Jun 4, 2026

BMRN (BioMarin Pharmaceutical Inc.) and KNSA (Kiniksa Pharmaceuticals, Ltd.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, BMRN returned -6.84%/yr vs 29.11%/yr for KNSA. At a 0.34 correlation, their price movements are largely independent.

Performance

BMRN vs. KNSA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in BioMarin Pharmaceutical Inc. (BMRN) and Kiniksa Pharmaceuticals, Ltd. (KNSA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, BMRN achieves a -8.03% return, which is significantly lower than KNSA's 16.00% return.

BMRN

• 1D: 2.51%
• 1M: -1.44%
• YTD: -8.03%
• 6M: 0.64%
• 1Y: -3.75%
• 3Y*: -16.34%
• 5Y*: -6.84%
• 10Y*: -4.86%

KNSA

• 1D: 1.98%
• 1M: -16.96%
• YTD: 16.00%
• 6M: 17.89%
• 1Y: 64.38%
• 3Y*: 48.51%
• 5Y*: 29.11%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

BMRN vs. KNSA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018
BMRN BioMarin Pharmaceutical Inc.	-8.03%	-9.58%	-31.83%	-6.83%	17.14%	0.75%	3.71%	-0.70%	-3.55%
KNSA Kiniksa Pharmaceuticals, Ltd.	16.00%	108.54%	12.77%	17.09%	27.27%	-33.39%	59.76%	-60.63%	44.27%

Correlation

The correlation between BMRN and KNSA is 0.25, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.25
Correlation (3Y) Calculated over the trailing 3-year period	0.28
Correlation (5Y) Calculated over the trailing 5-year period	0.35
Correlation (All Time) Calculated using the full available price history since May 25, 2018	0.34

The correlation between BMRN and KNSA shifts across timeframes, from 0.25 (1 year) to 0.35 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap BMRN : $10.80B KNSA : $3.94B
EPS BMRN : $1.37 KNSA : $0.92
PE Ratio BMRN : 39.85 KNSA : 51.96
PEG Ratio BMRN : 2.39 KNSA : 0.50
PS Ratio BMRN : 3.30 KNSA : 5.03
PB Ratio BMRN : 1.74 KNSA : 6.51
Total Revenue (TTM) BMRN : $3.24B KNSA : $754.05M
Gross Profit (TTM) BMRN : $2.46B KNSA : $294.06M
EBITDA (TTM) BMRN : $439.56M KNSA : $101.06M

Return for Risk

BMRN vs. KNSA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BMRN

BMRN Risk / Return Rank: 34
BMRN Sharpe Ratio Rank: 36
BMRN Sortino Ratio Rank: 32
BMRN Omega Ratio Rank: 32
BMRN Calmar Ratio Rank: 35
BMRN Martin Ratio Rank: 34

KNSA

KNSA Risk / Return Rank: 83
KNSA Sharpe Ratio Rank: 81
KNSA Sortino Ratio Rank: 81
KNSA Omega Ratio Rank: 79
KNSA Calmar Ratio Rank: 83
KNSA Martin Ratio Rank: 89

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BMRN vs. KNSA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for BioMarin Pharmaceutical Inc. (BMRN) and Kiniksa Pharmaceuticals, Ltd. (KNSA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	BMRN	KNSA	Difference
Sharpe ratio Return per unit of total volatility	-0.11	1.48	-1.59
Sortino ratio Return per unit of downside risk	0.10	2.38	-2.28
Omega ratio Gain probability vs. loss probability	1.01	1.30	-0.29
Calmar ratio Return relative to maximum drawdown	-0.17	3.06	-3.23
Martin ratio Return relative to average drawdown	-0.35	11.39	-11.74
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

BMRN vs. KNSA - Sharpe Ratio Comparison

The current BMRN Sharpe Ratio is -0.11, which is lower than the KNSA Sharpe Ratio of 1.48. The chart below compares the historical Sharpe Ratios of BMRN and KNSA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	BMRN	KNSA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.11	1.48	-1.59
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.21	0.55	-0.76
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.14	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.11	0.19	-0.08

Drawdowns

BMRN vs. KNSA - Drawdown Comparison

The maximum BMRN drawdown since its inception was -90.58%, which is greater than KNSA's maximum drawdown of -83.06%. Use the drawdown chart below to compare losses from any high point for BMRN and KNSA.

Drawdown Indicators

	BMRN	KNSA	Difference
Max Drawdown Largest peak-to-trough decline	-90.58%	-83.06%	-7.52%
Max Drawdown (1Y) Largest decline over 1 year	-22.49%	-21.12%	-1.37%
Max Drawdown (3Y) Largest decline over 3 years	-49.83%	-34.14%	-15.69%
Max Drawdown (5Y) Largest decline over 5 years	-57.64%	-53.17%	-4.47%
Max Drawdown (10Y) Largest decline over 10 years	-62.09%	—	—
Current Drawdown Current decline from peak	-63.35%	-19.55%	-43.80%
Average Drawdown Average peak-to-trough decline	-45.51%	-40.26%	-5.25%
Ulcer Index Depth and duration of drawdowns from previous peaks	10.84%	5.67%	+5.17%

Volatility

BMRN vs. KNSA - Volatility Comparison

BioMarin Pharmaceutical Inc. (BMRN) has a higher volatility of 15.30% compared to Kiniksa Pharmaceuticals, Ltd. (KNSA) at 10.38%. This indicates that BMRN's price experiences larger fluctuations and is considered to be riskier than KNSA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BMRN	KNSA	Difference
Volatility (1M) Calculated over the trailing 1-month period	15.30%	10.38%	+4.92%
Volatility (6M) Calculated over the trailing 6-month period	27.79%	33.56%	-5.77%
Volatility (1Y) Calculated over the trailing 1-year period	34.57%	43.77%	-9.20%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	32.87%	53.49%	-20.62%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	35.51%	63.66%	-28.15%

Dividends

BMRN vs. KNSA - Dividend Comparison

Neither BMRN nor KNSA has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

BMRN vs. KNSA - Profitability Comparison

The chart below illustrates the profitability comparison between BioMarin Pharmaceutical Inc. and Kiniksa Pharmaceuticals, Ltd. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

BMRN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, BioMarin Pharmaceutical Inc. reported a gross profit of 571.21M and revenue of 766.21M. Therefore, the gross margin over that period was 74.6%.

KNSA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported a gross profit of 0.00 and revenue of 214.27M. Therefore, the gross margin over that period was 0.0%.

BMRN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, BioMarin Pharmaceutical Inc. reported an operating income of 129.64M and revenue of 766.21M, resulting in an operating margin of 16.9%.

KNSA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported an operating income of 29.27M and revenue of 214.27M, resulting in an operating margin of 13.7%.

BMRN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, BioMarin Pharmaceutical Inc. reported a net income of 105.53M and revenue of 766.21M, resulting in a net margin of 13.8%.

KNSA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported a net income of 22.59M and revenue of 214.27M, resulting in a net margin of 10.5%.

Frequently Asked Questions

Can I hold both BMRN and KNSA in my portfolio?

BMRN and KNSA have a correlation of 0.25, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, BMRN or KNSA?

BMRN has higher volatility (15.30%) compared to KNSA (10.38%). In terms of maximum drawdown, BMRN dropped -90.58% vs KNSA's -83.06%.

Which has better risk-adjusted returns?

KNSA currently has the higher Sharpe Ratio (1.48 vs -0.11), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.